Skip to content
Open access

Association of age with clinical progression across plasma p-tau217 levels

Aug 2026 · medRxiv · 0 citations
Medicine

TL;DR

These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment and support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.

Abstract

Background

Chronological age and plasma p-tau217 each predicts cognitive decline, but whether their prognostic associations interact is unclear. In this study, we examined their joint associations in a memory-clinic cohort.

Methods

We included 3,741 participants from the Pittsburgh ADRC, with up to 28 years of follow-up (3.0 [IQR 2.0-6.0]). The primary outcome was increase in Clinical Dementia Rating global score (CDR-GS). Secondary outcomes included clinical-stage progression and longitudinal change in CDR Sum of Boxes. Plasma p-tau217 cut-off value was derived and externally validated in amyloid-beta-PET and autopsy sub-cohorts, respectively. Cox proportional hazards and linear mixed-effects models tested age-by-p-tau217 interactions while repeated cross-validation evaluated prognostic performance.

Results

Age and plasma p-tau217 interacted in their associations with CDR-GS progression ({chi}(1)2 = 23.94; p=9.81x10-7). Comparing the oldest displayed age with the youngest reference age, the adjusted hazard ratio (HR) was 4.80 (95% CI 2.74-8.27) in the lowest vs. 1.05 (95% CI 0.69-1.47) in the highest p-tau217 quartile. Older age was associated with clinical progression at low-p-tau217 (HR=1.97; 95% CI 1.58-2.45) but not at high-p-tau217 (HR=1.10; 95% CI 0.95-1.26) concentrations; adjusted 5-year risk differences were 19.3 and 3.3 percentage points, respectively. Adding plasma p-tau217 improved 5-year discrimination most accurately among participants younger than 60 years (AUC 0.66-0.81).

Discussion

Prognostic association between age and clinical progression varies by plasma p-tau217 concentration. Age stratifies risk at low plasma p-tau217 levels, whereas elevated p-tau217 identifies higher risk across age groups and attenuates the age-related gradient. These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.

Read PDF

Similar papers

Open access Aug 2026

Plasma p-tau217 and NfL predict incident dementia in the community

These findings support the use of blood-based biomarkers for population-level dementia risk stratification, underscore the value of combining markers to improve prognostic precision, and can aid clinicians using plasma p-tau217 or NfL in interpreting dementia risk.

A. Sunde, D. Tovar-Rios, A. Vik-Mo et al. · 0 citations
Open access Dec 2025

Developing Topics.

BACKGROUND Demonstrating the specificity of plasma biomarkers to AD-related neurodegeneration would add support to their prognostic and diagnostic clinical use. METHOD Participants from the Baltimore Longitudinal Study of Aging were cognitively unimpaired at the time of their plasma Aβ42/Aβ40, GFAP, NfL (Quanterix Ne...

Murat Bilgel, Ishaan Shah, Jasmine M. Cooper et al. · 0 citations
Open access Oct 2026

Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers.

BACKGROUND AND OBJECTIVES Plasma phosphorylated tau (p-tau) 217 is increasingly used for Alzheimer disease (AD) diagnosis and treatment decisions but may be discordant with established AD biomarkers. False-positive (FP) plasma results may lead to overtreatment and false-negative (FN) results to missed or delayed diseas...

D. Shir, A. Algeciras-Schimnich, Y. Piura et al. · 0 citations
Open access Sep 2026

Plasma P-tau217, APOE Genotype, and the Timing of Cognitive Impairment in individuals Across Diverse Racial and Ethnic Groups: A Pooled Analysis of Prospective Cohort Studies

Findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms and support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention.

Yue-Xuan Xu, T. I. Gunasekaran, Yian Gu et al. · 1 citation
Open access Aug 2026

Plasma p-Tau217 and SPECT-Based eZIS in Mild Cognitive Impairment: Concordance Analysis with Validation in an Amyloid PET Sub-Cohort

Plasma p-Tau217 showed a stronger association with cerebral amyloid pathology than eZIS indices in this elderly MCI cohort, and eZIS may provide complementary information regarding downstream neurodegenerative and cerebrovascular processes that are not directly captured by plasma biomarkers.

I-Lun Huang, Hiroshi Matsuda, Ya-Tang Pai et al. · 0 citations
Open access Aug 2026

CSF p-tau205: a biomarker of Alzheimer's disease progression and biological staging.

CSF p-tau205 as a biomarker of Alzheimer's disease pathology and progression with potential value for biological staging is supported and when incorporated into a conceptual CSF-based staging model, the final p-tau205-positive stage showed the strongest association with cortical atrophy, cognitive impairment, and risk...

J. Lantero-Rodríguez, S. Janelidze, S. Palmqvist et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.